Loading
A phase 1/2 trial of Zelenectide pevedotin and Pembrolizumab in bladder & urothelial cancer, triple-negative breast cancer, HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, non-small-cell lung cancer and ovarian cancer, run by BicycleTx Limited, active and no longer recruiting.
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies is a phase 1/2 interventional study registered as NCT04561362 by BicycleTx Limited, with 329 participants enrolled, started 2020-07-17 and due to reach its primary completion in 2026-03. Interventions recorded: BT8009 and Pembrolizumab.
Shares Zelenectide pevedotin, Bicycle Therapeutics, Peptide-drug & small-molecule-drug conjugates, Bladder & urothelial cancer and the tag pipeline.
Shares Zelenectide pevedotin, Bicycle Therapeutics, Peptide-drug & small-molecule-drug conjugates and the tag pipeline.
Shares Ovarian cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Ovarian cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Ovarian cancer, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Triple-negative breast cancer (TNBC), Pembrolizumab and the tag pipeline.
Shares Bicycle Therapeutics and the tag pipeline.
Shares Bicycle Therapeutics and the tag pipeline.